MAA Intelligence
Advancing Korean medical AI, together
The Medical AI Alliance connects biopharma, medical AI, devices and clinical networks. We publish 422 Korean listed medical companies and 42,000+ regulatory records in both Korean and English.
Healthcare innovation is fragmented. Collaboration is the missing layer.
Biopharma, AI, medical devices, and clinical institutions each hold critical pieces of the healthcare puzzle — but they rarely operate in a coordinated way. MAA exists to bridge that gap: providing a structured, governance-backed framework for organizations to collaborate, share capabilities, and build the future of medical AI together.
9
Alliance members spanning biopharma, AI, diagnostics, devices, security, and clinical networks
8
Members listed on the Korea Exchange, subject to public disclosure requirements
Multi-sector
Coverage across the full healthcare value chain, from R&D to clinical deployment
A strategic coordination layer for medical AI and healthcare.
MAA is not a product company. It is an alliance — a structured platform through which member organizations combine expertise, data capabilities, and industry networks to drive meaningful collaboration across the healthcare ecosystem.
Cross-sector membership
Formal alliance members include publicly listed leaders in biopharma, AI, diagnostics, patient monitoring, security infrastructure, and hospital networks.
Ecosystem governance
MAA provides the coordination structure — aligning interests, managing partnerships, and enabling responsible collaboration around healthcare data and technology.
Open to partners
Beyond formal membership, MAA works with startups, research institutions, hospitals, and government bodies as strategic partners in specific initiatives.
Nine organizations. One ecosystem.
MAA members represent the full healthcare value chain — from drug development and AI diagnostics to clinical infrastructure and digital trust.
Latest from the alliance.
Hanmi Pharmaceutical's Eppe Approved as Korea's First Homegrown GLP-1 Obesity Drug
Korea's MFDS approved Hanmi's Eppe for chronic weight management, the first domestically developed GLP-1 obesity drug; Q4 2026 launch planned at ~30% below Wegovy.
Read original →Hanmi Pharmaceutical Wins MFDS Approval for Korea's First Homegrown GLP-1 Obesity Drug
Korea's MFDS approved Hanmi's Efe auto-injector (2–10mg), the country's first domestically developed GLP-1 obesity drug, with commercial launch planned for October 2026.
Read original →Siloam Hospitals to Open Semarang Srondol Facility as H2 2026 Expansion Continues
Siloam Hospitals (SILO) plans to open Siloam Hospitals Semarang Srondol imminently, continuing steady network expansion with 4,440 operational beds at 62.5% occupancy.
Read original →Let your AI query this index directly
Connect this index to ChatGPT, Claude, Cursor or any MCP-capable tool, and your AI can look up company profiles, products, R&D, three years of financials, and regulatory and clinical records for 422 listed Korean medical companies as it answers. No download, no sign-up — paste one URL. Free and read-only.
https://medicalaialliance.org/api/mcpBuild the future of healthcare with us.
MAA welcomes organizations that are serious about healthcare innovation — whether as a formal member or as a strategic partner.